Skip to content

Study · Animal study (in vivo) · rat · 2001

1 result

GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R and 4 more

Show all authors

Riviere P, Trojnar J, Junien JL, Rivier JE

Journal of medicinal chemistry1 Feb 2001Cited by 77 (Europe PMC)

PMID11462984 (opens in a new tab)DOI10.1021/jm0003900 (opens in a new tab)PepBankPUB-11462984
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In intact rats, ganirelix inhibited plasma testosterone for 1 day after subcutaneous administration at 2 mg/kg in 5% mannitol.

    In plain wordsIn rats, ganirelix inhibited plasma testosterone for 1 day.

    Peptide
    Ganirelix
    Outcome
    DecreasePlasma testosterone inhibition duration
    Study

    ratn: not reported in source

    Intact rat
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg/kg · subcutaneousAs given in this study (rat).

    Measurements

    Testosterone inhibition duration
    1 days
    ganirelix 2 mg/kg s.c.

    Source sentences

    Summary
    In the intact rat, ganirelix, abarelix, azaline B, and FE200486 inhibited plasma testosterone for 1, 1, 14, and 57 days, respectively, at 2 mg/kg s.c. in 5% mannitol (injection volume = 20 microL).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.